MiddleBrook Pharmaceuticals Announces $20 Maximum Copay Program for MOXATAG®
15 Julho 2009 - 8:13AM
Business Wire
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), announced
today that it has implemented a $20 maximum copay program for
MOXATAG (amoxicillin extended-release) Tablets, 775 mg. The program
is designed to keep a patient�s net out-of-pocket copay expense for
a MOXATAG prescription at $20 or less. Today, MiddleBrook�s 300
field force representatives and district managers will begin
supplying physicians with MOXATAG $20 maximum copay voucher cards
to distribute to patients with MOXATAG prescriptions. Patients can
redeem the voucher at the point-of-sale in conjunction with having
a MOXATAG prescription filled.
�In this tough economy, we recognized the need to improve
MOXATAG�s affordability to the patient. This $20 maximum copay
program will replace our current $15 point-of-sale copay check
program, which has been in place since MOXATAG�s launch,� said John
Thievon, president and chief executive officer of MiddleBrook. �We
believe MOXATAG is an excellent first-line therapy for strep
throat, and with this $20 maximum copay program for MOXATAG, we can
minimize much of the pricing pressure at the patient level. We are
delighted to implement this valuable program across the country
effective today.�
About MiddleBrook
Pharmaceuticals:
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a
pharmaceutical company focused on developing and commercializing
anti-infective products that fulfill unmet medical needs.
MiddleBrook has developed a proprietary delivery technology called
PULSYS�, which enables the pulsatile delivery, or delivery in rapid
bursts, of certain drugs. The Company is currently developing a
portfolio of anti-infective PULSYS products. MiddleBrook�s
near-term corporate strategy is to improve dosing regimens and/or
reduce frequency of dosing which it believes will result in
improved patient dosing convenience and compliance for antibiotics
that have been used and trusted by physicians and patients for
decades. MiddleBrook currently markets KEFLEX�, the
immediate-release brand of cephalexin, and MOXATAG � the first and
only FDA-approved once-daily amoxicillin. For more information
about MiddleBrook, please visit www.middlebrookpharma.com.
About MOXATAG:
MOXATAG (amoxicillin extended-release) Tablets, 775mg, is a
once-a-day extended-release formulation of amoxicillin for oral
administration consisting of three components: one
immediate-release component and two delayed-release components. The
three components of MOXATAG are combined in a specific ratio to
prolong the release of amoxicillin compared to immediate-release
amoxicillin. MOXATAG is intended to provide a lower treatment dose,
once-daily alternative to currently approved penicillin and
amoxicillin regimens for the treatment of adults and pediatric
patients 12 years and older with tonsillitis and/or pharyngitis.
For more information about MOXATAG, please visit
www.moxatag.com.
FORWARD-LOOKING STATEMENTS:
Some of the statements contained in this press release contain
forward-looking statements, within the meaning of the Securities
Exchange Act of 1934 and the Securities Act of 1933, that reflect
our current plans, beliefs, estimates and views with respect to,
among other things, future events and financial performance. In
some cases, forward-looking statements are identified by words such
as �believe,� �anticipate,� �expect,� �intend,� �plan,�
�potential,� �estimate,� �will,� �may,� �predict,� �should,�
�could,� �would� and similar expressions. You should not place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. You should not regard
the inclusion of this forward-looking information as a
representation by us or any other person that we will achieve the
future plans, estimates or expectations contained in this press
release. You should specifically consider the factors identified in
this press release that could cause actual results to differ. In
addition, there are or will be important factors that could cause
our actual results to differ materially from those in the
forward-looking statements. We believe these factors include, but
are not limited to, those identified in the sections titled
�Management�s Discussion and Analysis of Financial Condition and
Results of Operations� and �Risk Factors� in our Annual Report on
Form 10-K filed with the Securities and Exchange Commission (the
�SEC�) and in similar disclosures made by us from time to time in
our other filings with the SEC. We operate in a continually
changing business environment, and new risks and uncertainties
emerge from time to time. Management cannot predict these new risks
or uncertainties, nor can it assess the impact, if any, that any
such risks or uncertainties may have on our business or the extent
to which any factor, or combination of factors, may cause actual
results to differ from those projected in any forward-looking
statement. Accordingly, the risks and uncertainties to which we are
subject can be expected to change over time, and we undertake no
obligation to update publicly or review the risks or uncertainties
described in this press release. We also undertake no obligation to
update publicly or review any of the forward-looking statements
made in this press release, whether as a result of new information,
future developments or otherwise. If one or more of the risks or
uncertainties referred to in this press release materialize, or if
our underlying assumptions prove to be incorrect, actual results
may vary materially from what we have projected. We qualify all of
our forward-looking statements by these cautionary statements.
KEFLEX, KEFLEX 250 MG, KEFLEX 500MG, KEFLEX 750 MG, MiddleBrook,
MiddleBrook Pharmaceuticals (stylized), MiddleBrook
Pharmaceuticals, Inc., M1 (stylized), MOX-10, MOXAKIT, MOXATAG1
(stylized), MOXATAG, MOXATEN, MOXPAK, MOX-PAK and PULSYS are our
trademarks and have been registered in the U.S. Patent and
Trademark Office or are the subject of pending U.S. trademarks
applications. Each of the other trademarks, tradenames, or service
marks appearing in this document belongs to the respective holder,
as used herein, except as otherwise indicated by the context.
References to �we,� �us,� �our,� �MiddleBrook,� or the �Company,�
refer to MiddleBrook Pharmaceuticals, Inc., and its
subsidiaries.
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024